Latest News & Features
Unified Patent Court
The UPC Court of Appeal’s approach to delivering a preliminary injunction in a glucose sensor dispute has far-reaching effects, as Wouter Pors of Bird & Bird explains. 27 February 2025
Europe
Concerns over misuse, side effects and counterfeits are tightening controls on the blockbuster treatments, says Iona Silverman of Freeths. 27 February 2025
Europe
Following approval of a new European patent, the licensing company’s CEO and GC accept that ‘tactical retreats and tactical gains’ are baked into its portfolio’s future, finds Marisa Woutersen. 27 February 2025
Americas
Former Latham & Watkins global vice chair joins the firm as co-chair of its technology transactions practice | New partner brings experience in biotechnology, life sciences, technology, artificial intelligence and sustainable energy. 27 February 2025
Europe
The company’s nine-country ban against a Chinese rival saw the court adopt a broad interpretation of means-plus-function claims, increasing the risk for infringers even if they modify products. Marisa Woutersen unpacks the debate over the UPC’s flexible approach to added matter and the urgency criteria. 25 February 2025
Biotechnology
Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing technology found invalid | Natera also faces separate trade secrets claims from Guardant Health over cancer blood tests. 25 February 2025
Americas
Smaller US companies can now choose to take on much larger, foreign opponents at the ITC, explain Cristen Corry, Paul Ainsworth and Uma Everett of Sterne Kessler. 25 February 2025
Americas
British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent infringement | Earlier ruling ‘nullifies a statutory mechanism for expediting access to generic drugs and breaks sharply with precedent on inducement’ says UK pharma company. 20 February 2025
Americas
Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments. 20 February 2025
Americas
Patent Trial and Appeal Board rules all challenged claims were unpatentable | Decision follows Federal Circuit review that revived Apple’s challenge. 18 February 2025